Why the study?
Is pregnancy safe in patients with hypertrophic cardiomyopathy, and what are the effects of beta-adrenergic blocking drugs on fetal outcomes?
Is pregnancy safe in patients with hypertrophic cardiomyopathy, and what are the effects of beta-adrenergic blocking drugs on fetal outcomes?
Pregnancy is generally safe in patients with hypertrophic cardiomyopathy, but beta-blockers should be used cautiously due to potential fetal risks such as bradycardia and small-for-dates babies.
Answers are grounded in this paper and cite their sources.
Warrants fetal monitoring with beta-blockers in HCM pregnancies; leaves open optimal management pending larger prospective studies.
The outcome of 54 pregnancies in 23 patients with hypertrophic cardiomyopathy was analysed. No mother or infant died in the perinatal period. Six patients developed dyspnoea requiring treatment with diuretics. Beta-adrenergic blocking drugs were given in 18 pregnancies and three of the infants in this were small for dates and in two fetal bradycardia occurred. The results comfirmed that pregnancy is safe in patients with hypertrophic cardiomyopathy. A flexible approach should be adopted towards administering beta-adrenergic blocking drugs to pregnant women with hypertrophic cardiomyopathy. Many such patients do well without these drugs and can thus avoid the potential hazards--namely, small-for-dates babies and fetal bradycardia--that are associated with them.
No takes yet. Share an insight, caveat, or question.
Oakley et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: